{"id":"W4394062100","doi":"10.1001/jamacardio.2024.0959","title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia","year":2024,"lang":"en","type":"article","venue":"JAMA Cardiology","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Novo Nordisk; Arrowhead Pharmaceuticals; Esperion Therapeutics; Amgen","keywords":"Medicine; Hypertriglyceridemia; Triglyceride; Placebo; Internal medicine; Tolerability; Gastroenterology; Endocrinology; Dose-ranging study; Apolipoprotein B; Acute pancreatitis; Cholesterol; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002862559,0.0001642206,0.0005652625,0.0001260756,0.00005017633,0.00002624121,0.0000849842,0.0002874207,0.00008189159],"category_scores_gemma":[0.000381663,0.0001262255,0.0003692028,0.0001663065,0.00008832831,0.00009182391,0.00003516235,0.0002309929,0.0001936523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003584133,"about_ca_system_score_gemma":0.0001834732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002053696,"about_ca_topic_score_gemma":0.000001788593,"domain_scores_codex":[0.9988636,0.0000528631,0.0002255936,0.000384739,0.0001106526,0.0003625994],"domain_scores_gemma":[0.9991995,0.000261625,0.00002084149,0.0003128492,0.00007125165,0.000133897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001363394,0.0000440749,0.01336998,0.001004906,0.001095541,0.0003548789,0.0005138656,0.00007587195,0.009772799,0.02227729,0.7420563,0.2080711],"study_design_scores_gemma":[0.002068454,0.0001888658,0.007761282,0.00004117198,0.000337125,0.0007544325,0.0001608393,0.0002198617,0.0002571346,0.00157751,0.9864718,0.0001615415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7580326,0.03729113,0.007971117,0.02368083,0.01167265,0.002240937,0.0003300623,0.001140982,0.1576397],"genre_scores_gemma":[0.9845919,0.0005948881,0.001398102,0.003788152,0.004803851,0.00015044,0.0001508798,0.00005840028,0.004463366],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2444155,"threshold_uncertainty_score":0.5147327,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02024560358429529,"score_gpt":0.2954680707326398,"score_spread":0.2752224671483445,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}